抗RAS治疗新时代:放疗临床试验的独特挑战与机遇
本文综述了胰腺导管腺癌(PDAC)中新型等位基因特异性及RAS-ON多选择性直接RAS抑制剂的进展,指出这些药物正在改变PDAC标准治疗,并探讨其对放疗临床试验设计、解读和临床相关性的影响。文章回顾了全身治疗变化如何影响PDAC放疗关键试验,并考虑了对当前和未来试验的启示。
要点
- 直接RAS抑制剂正在改变PDAC全身治疗格局,影响放疗试验设计。
- PDAC放疗试验因全身治疗同步演变而设计复杂、解读困难。
- 新RAS靶向治疗时代,重新审视放疗试验的临床相关性更为关键。
核心结论
- 新型RAS靶向治疗的出现使PDAC放疗临床试验的设计与解读面临更大挑战,需重新考虑试验框架。
研究设计与样本
- 本文为综述,回顾全身治疗变化对PDAC放疗关键试验的影响,并讨论对未来试验的启示。
主要发现
- 等位基因特异性及RAS-ON多选择性直接RAS抑制剂在PDAC中取得前所未有的系统治疗进展。
- 这些药物已改变PDAC标准治疗,并对局部治疗如放疗的 ongoing 和未来试验产生影响。
- 数十年来PDAC放疗临床试验提出的问题多于答案,全身治疗同步演变是主要挑战之一。
临床怎么用
- 在PDAC放疗临床试验设计中,需考虑新型RAS靶向治疗对全身治疗背景的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of effective allele-specific and RAS-ON multiselective direct RAS inhibitors for pancreatic ductal adenocarcinoma (PDAC) represents unprecedented progress in systemic therapy for a devastating disease. These drugs are already changing the standard of care in PDAC, and their development raises important questions about how ongoing and future trials of local therapies such as radiotherapy (RT) may be affected. Although RT remains part of the therapeutic armamentarium for pancreatic ductal adenocarcinoma (PDAC), particularly in locally advanced disease and the adjuvant setting, decades of clinical trials have raised more questions than they have answered. One major challenge has been the concurrent evolution of systemic therapies, complicating the design, interpretation, and clinical relevance of RT trials. Here, we review how changes in systemic therapy have influenced seminal trials of RT for PDAC and will consider implications for ongoing and future trials in this space. These considerations, already relevant when options were more limited, are even more critical with the emergence of novel RAS-targeted therapies.
引用
- Ellsworth SG, Olivier T. A new era in anti-RAS therapy: Unique challenges and opportunities for radiotherapy clinical trials. Eur J Cancer. 2026. PMID: 42913256. doi:10.1016/j.ejca.2026.117790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。